The kidneys play a fundamental role in the long-term control of arterial pressure by regulating sodium balance and extracellular fluid volume. The renin-angiotensin system (RAS) is at the center of the regulation of hypertension and progressive renal injury. It has gradually become clear that not only systemic RAS, but also intrarenal RAS has specific effects in the pathogenesis and progression of hypertension and renal damage. All of the RAS components are exhibited in the kidney and intrarenal angiotensin II (Ang II) is formed by multiple mechanisms. The demonstration of much enhanced levels of Ang II within specific renal compartments points out selective local regulation of Ang II in the kidney, showing that intrarenal Ang II levels are regulated in a way different from circulating Ang II. The importance of the RAS in involving proper nephrogenesis is also well known, and suppression of the RAS during fetal development may play a key role in mediating the structural and physiological changes observed in models of fetal programming of hypertension.
Introduction
The systemic role of the renin-angiotensin system (RAS) in the regulation of blood pressure and volume homeostasis and in the pathophysiology of hypertension (HTN) has been targeted for many decades 1) . Increased RAS activity is also a major determinant for numerous pathologic conditions because angiotensin II (Ang II) increases aldosterone and blood pressure and contributes to the development of end-organ damage through direct effects on cardiac, vascular, and renal tissues 2) .
As is well known, Ang II is produced systemically. The substrate of the RAS, angiotensinogen (AGT) is released from the liver and is cleaved in the circulation by renin that is secreted from the juxtaglomerular apparatus of the kidney to form Ang I. Then, angiotension I (Ang I) is easily activated to Ang II by angiotensin converting enzyme (ACE), which is predominantly expressed in high levels on the surface of endothelial cells in the pulmonary circulation 3) . Ang II, considered as the most powerful active product of the RAS, acts on specific receptors.
Notably, this view of the RAS has been expanded by more recent findings that increased the complexity of the system. Different Ang receptors and signal transduction pathways have been described. Moreover, additional other peptides such as Ang 1~7, have been recognized, and alternative pathways of Ang II formation, for example, by the serine protease chymase have been proposed 4) (Fig. 1) . The resulting alteration of our inspection of the RAS has introduced the concept of "local" or "tissue" RAS 2) . Among these, the pathophysiological implications of the intrarenal . Additionally, numerous epidemiological and experimental studies have provided the profound involvement of the RAS in the fetal programming of hypertension and adult disease 7, 8) . Programming during fetal life occurs aligned with an adverse fetal environment and leads to long-term adaptive responses that lead to structural and physiological changes and the subsequent development of HTN 9, 10) .
In this review, we will summarize the physiologic actions of Ang II including the intrarenal RAS and the recent findings associated with its roles in the pathogenesis of HTN. We will also discuss evidence regarding the effects of the intrarenal RAS on fetal programming of HTN. .
Physiologic effects of angiotensin II
In the kidney, Ang II participates in vascular, tubular, and growth-promoting activities. Administration of exogenous Ang II decreases renal blood flow and glomerular filtration rate (GFR), and constricts afferent and efferent arterioles dose-dependently 11) . Afferent arteriole vasoconstrictor responses to Ang II are mediated by Ang II type 1A (AT1A) and 1B (AT1B) receptors, whereas efferent arteriolar vasoconstrictor responses to Ang II are mediated by only AT1A receptors in the mouse kidney 12) . Ang II also reduces the glomerular filtration coefficient while increasing afferent and efferent arteriolar resistances, which contributes to the decreases in GFR.
Acute Ang II infusion sufficient to change renal hemodynamics does not cause proteinuria. However, sustained elevation of intrarenal Ang II induces proteinuria accompanied by progressive injury of the glomerular filtration barrier, which is composed of the glomerular endothelium, glomerular basement membrane, and podocytes 13) . . It may also be difficult to maintain the GFR by sufficient increases in the glomerular filtration coefficient when glomerular pressure is reduced by treatment with ACE inhibitors and AT1 receptor blockers (ARBs) 14) .
Ang II also exerts a modulatory effect on the sensitivity of the tubuloglomerular feedback mechanism, which pro- . Ang II-induced growth effects are also implicated in the development of glomerulosclerosis and tubulointerstitial fibrosis and antagonizing these effects is a primary target of renoprotection modality in clinical nephrology.
Intrarenal renin-angiotensin system
Though every organ system has components of the RAS, the kidney is exclusive in having every element of the RAS with compartmentalization in the tubular and interstitial networks as well as intracellular accumulation 14) . Not surprisingly, the key role of tissue as well as classical RAS in blood pressure regulation has well been recognized.
Angiotensinogen
Human AGT is expressed in multiple tissues, including liver, adipose tissue, heart, vessel wall, brain, and kidney.
The human AGT glycoprotein contains a signal peptide that is removed cotranslationally to yield the substrate of renin. Whereas AGT is constitutively secreted, recent evidence suggests that the protein may localize in the nucleus of some cells. Intrarenal AGT mRNA and protein are localized to proximal tubule cells, suggesting that the intratubular Ang II could be derived from locally formed and secreted AGT 19) . The proximally formed AGT is screted into the tubular fluid and flows into the distal nephron, allowing intraluminal Ang II formation to continue throughout the nephron with the residual AGT appearing in the urine.
Plasma AGT levels are close enough to the Michaelis constant for renin that small increases in either renin or AGT may increase Ang II production and alter blood pressure 14) . Notably, elevated renal-specific expression of AGT causes systemic hypertension without a change in circulating Ang II. AGT expression may exert their effects in a tissue-specific manner and not necessarily by changing plasma AGT. Transgenic mice overexpressing rat AGT gene in the kidney significantly increased blood pressure, albuminuria, and renal injury; and administration of ARB or ACE inhibitor reversed these abnormalities 20) .
Renin and prorenin
Renin is an aspartyl-protease that exists in two forms, the proenzyme prorenin and mature renin. The secreted mature renin has 339 to 343 amino acid residues after pro- In the kidney, the recently described renin receptor binds renin and prorenin, leading to an increase in the catalytic efficiency of Ang I formation from AGT 21) . The direct renin inhibitor may be a more acceptable access to inhibiting the RAS as it inhibits renin binding to AGT, which is ultimately the rate-limiting step in Ang II production. There is also a supporting evidence that the binding of renin to the receptor can have profibrotic effects that are independent of Ang II, suggesting direct actions of renin and prorenin on organ pathophysiology 22) .
Renin itself or prorenin may directly affect cellular effects. .
Alternative pathway
Increasing evidence has shown that alternative pathways to the ACE exist for the Ang II generation in the heart, arteries, and kidney. Of these, the chymase-dependent pathway is thought to be the most important, as Ang II formation is substantially blocked by chymase inhibitors. More than 80% of Ang II formation in the human heart and more than 60% of that in arteries seems to be chymase-dependent, and recent studies support the potential contribution of chymase-dependent intrarenal Ang II formation to the progression of renal injury. ACEknockout mice have shown that local Ang II generation within the kidney is unchanged due to a 14-fold increase in the chymase activity 29) and intra-arterial infusion of a chymase inhibitor significantly diminished intrarenal Ang II in the ischemic kidney 30) . Clinical studies reported increased chymase expression in rejected kidneys and kidneys of patients with renovascular hypertension and diabetes.
In the classic pathway of RAS, Ang II is a product of a "peptidyl dipeptidase" ACE. In this process, the decapep- 31) . The ACE2 knockout model also exhibited a greater degree of glomerulosclerosis and proteinuria, which was attenuated by AT1 receptor blockade 32) . Thus, ACE2 seems to control Ang II production by ACE, either by stimulating an alternative pathway for Ang I degradation or by promoting the convertsion of Ang II to Ang1-7 ( Fig. 1) .
Recent research for renin-angiotensin system and hypertension . Elevated concentrations of tubular Ang II were associated with proteinuria and interstitial cell infiltration. In patients with IgA nephropathy, glomerular expression of renin, ACE, chymase, AT1 receptors, and AT2 receptors was also increased, which correlated with the degree of mesangial hypercellularity and expansion 43) .
Immunoreactive renin, AGT, ACE, Ang II receptor, and
Ang II peptide are present in cysts and in the dilated tubules of kidneys in autosomal dominant polycystic kidney disease 44) . ACE-independent and chymase-mediated Ang II formation has been reported in the interstitium of kidney tissue in autosomal dominant polycystic kidney disease 45) . 
